Xyzagen Presents Research on CPL-01 at ASPET 2023
Pittsboro, NC, May 12, 2023
Xyzagen, Inc., a pharmacokinetics consultancy and boutique CRO, in support of Cali Biosciences, presented new findings on CPL-01, a novel extended-release ropivacaine, at the American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting. The conference held May 6-10, 2023, in St. Louis, Missouri, provided a platform to discuss innovations in sustained release local pain medication for post-surgical pain management.
The study, titled “CPL-01, A Novel Extended-Release Ropivacaine, Demonstrates Consistent and Predictable Systemic Exposure Compared to Liposomal Bupivacaine in Multiple Surgical Models”, emphasized the consistent pharmacokinetics (PK) of CPL-01 across different surgical models. This development addresses key challenges with current long-acting local anesthetics, including variability in drug release and systemic exposure, which often limit their adoption in clinical settings.
Presentation Summary
About Xyzagen
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen accelerates early-phase drug development through its proprietary First-in-Rat® and First-in-Mouse® discovery platforms. The company also supports late-stage clinical pharmacokinetics, population PK modeling, and quantitative medicine.
Xyzagen’s boutique structure ensures personalized, expert collaboration with small clients during critical stages of drug development, from candidate selection to pre-NDA meetings.
